Genetic studies of cancer patients and their families

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the genetic and behavioral factors that may contribute to the development of specific cancers in patients with a history of cancer and their relatives. The primary objectives include identifying rare cancer patients and families with genetic susceptibility to cancer and determining how heredity and biomarkers influence clinical outcomes. Participants will provide various biospecimens, including blood and saliva, and complete questionnaires to gather comprehensive data on their cancer history and family background.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals must have a personal history of cancer and/or a family history of cancer suggestive of the presence of an inherited predisposition. This inherited predisposition might manifest as:

  * Young age cancer diagnosis
  * Multiple primary neoplasms in affected member
  * The presence of rare tumor types in the family
  * Congenital malformations
  * Any other family clustering of cancer
  * Any other cancer-predisposing genetic diseases/conditions
* Individuals may also be eligible by participation in the City of Hope Cancer Screening \& Prevention Program Network (CSPPN) clinical service or on the basis of membership in a group known or suspected to have an increased risk of carrying a genetic alteration or of sustaining a particular exposure that would place that at increased risk of cancer. (Examples would include members of occupational cohorts like asbestos workers, individuals with multiple dysplastic nevi in the absence of a family history of cancer, and individuals descended from a particular tribe in the American Southwest who have an increased incidence of a rare genetic alteration associated with an increased risk of a specific cancer.)
* Individuals and families may be referred to us in a number of different ways. After initial contact is made with a individual or family by family studies personnel; an individual within the bloodline will be identified as the historian. There may be more than one historian within a family
* At least one historian must be wiling to provide information or access as needed to contact appropriate family members for documentation of cancer and for consent. An individual is considered to be eligible to participate if they criteria; contact with relatives is not always indicated
* Individuals who are under 18 are eligible for study if they meet the criteria. Consent for participation must be given by a legal guardian or parent
* Deceased patients may be included in the study. Public records, such as death certificates, can be used to confirm information from individuals or family members. If medical records are needed, consent for these records will be obtained from the deceased's next of kin. Next of kin refers to the following hierarchy of relatives; spouse, offspring, parents, and siblings. (Any further use of next of kin in this protocol should relate back to this hierarchy.) Archived tissue samples, such as pathology blocks or snap frozen tumor from a pathology department tumor bank (discard specimens) may be used for genetic research

Exclusion Criteria:

* A family may be ineligible for study if the historian will not allow access to anyone within the family and thus, the accuracy of the family history cannot be established

Where it's running

• Valleywise Comprehensive Health Center - Phoenix
  Phoenix, Arizona, United States Recruiting
• John Muir Medical Center-Concord Campus
  Concord, California, United States Recruiting
• City of Hope Medical Center
  Duarte, California, United States Recruiting
• Saint Jude Medical Center
  Fullerton, California, United States Recruiting
• Saddleback Memorial Medical Center
  Laguna Hills, California, United States Recruiting
• USC / Norris Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Stephen Gruber, MD — City of Hope Medical Center
• Study coordinator: Stephen Gruber
• Email: sgruber@coh.org

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• Belzutifan in adolescents with solid tumors

  This study tests belzutifan in teenagers whose solid tumors can't be removed by surgery or have spread.

  Recruiting at 10 sites Phase 2 Merck Sharp & Dohme LLC · Iowa City, Iowa and 9 other locations · NCT07700758

• Ifinatamab Deruxtecan in kids with relapsed or refractory solid cancers

  This study tests whether I-DXd can help children whose solid tumors have come back or not responded to previous treatments.

  Recruiting at 35 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 34 other locations · NCT07630974

• MK-4884 safety in advanced solid tumors

  This early-phase study tests different doses of MK-4884 to see if it is safe and tolerable for adults with certain advanced solid cancers.

  Recruiting at 10 sites Phase 1 Merck Sharp & Dohme LLC · St Louis, Missouri and 9 other locations · NCT07600749

• PET scan targeting CDH3 for lung tumors

  This will test whether a new PET imaging agent called 68Ga-TOI-1 that targets CDH3 can better detect and stage lung tumors and help tell malignant from benign pulmonary nodules in adults with suspected or confirmed non-small cell lung cancer.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07487883

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.